Free Trial

Poseida Therapeutics (PSTX) Insider Trading & Ownership

Poseida Therapeutics logo
$2.72 -0.05 (-1.81%)
(As of 11/20/2024 ET)

Poseida Therapeutics (NASDAQ:PSTX) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
2.90%
Number Of
Insiders Buying
(Last 3 Years)
3
Amount Of
Insider Buying
(Last 3 Years)
$8.54 M
Number Of
Insiders Selling
(Last 3 Years)
1
Amount Of
Insider Selling
(Last 3 Years)
$592,968.24
Get PSTX Insider Trade Alerts

Want to know when executives and insiders are buying or selling Poseida Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

PSTX Insider Buying and Selling by Quarter

Poseida Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/8/2022Eric OstertagChairmanBuy142,857$3.50$499,999.50  
8/8/2022Life Sciences Holdings L MalinMajor ShareholderBuy2,150,000$3.50$7,525,000.00  
8/3/2022Eric OstertagChairmanSell160,696$3.69$592,968.24  
3/16/2022Kerry D IngallsCOOBuy3,000$3.98$11,940.00  
12/6/2021Life Sciences Holdings L MalinDirectorBuy1,828$6.90$12,613.20  
12/1/2021Life Sciences Holdings L MalinDirectorBuy18,365$6.85$125,800.25  
11/29/2021Life Sciences Holdings L MalinDirectorBuy11,057$6.89$76,182.73  
11/26/2021Life Sciences Holdings L MalinDirectorBuy27,251$6.81$185,579.31  
11/23/2021Life Sciences Holdings L MalinDirectorBuy14,625$6.77$99,011.25  
(Data available from 1/1/2013 forward)

PSTX Insider Trading Activity - Frequently Asked Questions

The list of insiders at Poseida Therapeutics includes Eric Ostertag, Kerry D Ingalls, and Life Sciences Holdings L Malin. Learn more on insiders at PSTX.

2.90% of Poseida Therapeutics stock is owned by insiders. Learn more on PSTX's insider holdings.

Poseida Therapeutics Key Executives

  • Mr. Mark J. Gergen J.D. (Age 61)
    Executive Chairman of the Board
    Compensation: $961.8k
  • Dr. Kristin Yarema Ph.D. (Age 53)
    President, CEO & Director
    Compensation: $711.99k
  • Ms. Johanna M. Mylet CPA (Age 36)
    Chief Financial Officer
  • Mr. Loren Wagner
    Chief Operations Officer
  • Ms. Kristin Martin
    Chief People & Administration Officer
  • Mr. Alexander Chapman
    Senior VP of Investor Relations & Corporate Communications
  • Mr. Harry J. Leonhardt Esq. (Age 67)
    J.D., General Counsel, Chief Compliance Officer & Corporate Secretary
    Compensation: $630.23k
  • Dr. Devon J. Shedlock Ph.D.
    Chief Scientific Officer of Cell Therapy
  • Ms. Lisa Portale
    Senior Vice President of Regulatory Affairs
  • Dr. Jeffrey W. Winkelman J.D.
    Ph.D., Senior VP & Chief Patent Counsel


This page (NASDAQ:PSTX) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners